Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022, 166(3):290-296 | DOI: 10.5507/bp.2021.028

Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes

Jana Tesarikovaa, Pavel Skalickya, Daniela Kurfurstovab, Hana Svebisovac, Ondrej Urband, Premysl Faltd, Jana Zapletalovae, Dusan Klosa, Martin Loveceka
a Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
b Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
c Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
d Department of Internal Medicine II - Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
e Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Background: The aim of this study was to evaluate symptoms, diagnostic methods, short- and long-term outcomes of surgical treatment in patients with duodenal adenocarcinoma.

Patients and Methods: A single center, retrospective, observational study of 52 consecutive patients with duodenal adenocarcinoma operated on with curative intent between 2006 - 2019. Duodenectomy as part of a hemipancreatoduodenectomy or total pancreatectomy procedure was performed for ADAC (ampullary duodenal/intestinal adenocarcinoma) or NADAC (non-ampullary duodenal adenocarcinoma).

Results: Prevailing symptoms were obstructive jaundice in the ADAC group (P<0.0001) and bleeding in the NADAC group (P=0.005), with larger tumor size in patients with NADAC (P=0.001). Complication rate, morbidity and mortality were comparable. Primary total pancreatoduodenectomy predominated in the NADAC group, 16.6% vs. 2.9%, and salvage completion pancreatectomy in the ADAC group, 6% vs. 0%. Significant prognostic factors for OS were perineural invasion (P=0.006) and adjuvant chemotherapy (P=0.045) in the ADAC group, and for DFS the total number of resected lymph nodes (P=0.042) and lymph node ratio (P=0.031) in the NADAC group. Median OS is 21 months and 5-year survival 27.3% in the NADAC group and 41.5 months and 52% in the ADAC group.

Conclusion: Ampullary duodenal/intestinal adenocarcinomas are smaller than non-ampullary at diagnosis, with a higher rate of lymph node metastases, but with a better prognosis and long-term outcome in the presented cohort. Oral localisation of NADAC prevailed in the present cohort. Perineural invasion and postoperative oncological therapy are significant prognostic factors for OS in ADAC, but the total number of lymph nodes and lymph node ratio are significant prognostic factors for DFS in NADAC.

Keywords: duodenal carcinoma, non-ampullary carcinoma, ampullary carcinoma, outcomes, long-term survival

Received: January 15, 2021; Revised: April 23, 2021; Accepted: April 23, 2021; Prepublished online: May 11, 2021; Published: September 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesarikova, J., Skalicky, P., Kurfurstova, D., Svebisova, H., Urban, O., Falt, P., ... Lovecek, M. (2022). Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes. Biomedical papers, 166(3), 290-296. doi: 10.5507/bp.2021.028
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chandrasegaram MD, Gill AJ, Samra J, Price T, Chen J, Fawcett J, Merrett ND. Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol 2017;9:407-15. doi: 10.4251/wjgo.v9.i10.407 Go to original source... Go to PubMed...
    2. Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol 2013;44:2792-8. doi: 10.1016/j.humpath.2013.07.030 Go to original source... Go to PubMed...
    3. Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinico-pathological analysis. World J Gastroenterol 2007;13:1108-11. doi: 10.3748/wjg.v13.i7.1108 Go to original source... Go to PubMed...
    4. Reghunath A, Kabilan K, Mittal MK. Exploring the neglected segment of the intestine: the duodenum and its pathologies. Pol J Radiol 2020;85:e230-e244. doi: 10.5114/pjr.2020.95477. PMID: 32612721; PMCID: PMC7315055. Go to original source... Go to PubMed...
    5. Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, Bagci P, Basturk O, Bandyopadhyay S, Jang KT, Kooby DA, Maithel SK, Sarmiento J, Staley CA, Gonzalez RS, Kong SY, Goodman M. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol 2012;36:1592-608. doi: 10.1097/PAS.0b013e31826399d8 Go to original source... Go to PubMed...
    6. Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: Advances in diagnosis and surgical management. World J Gastrointest Surg 2016;8:212-21. doi: 10.4240/wjgs.v8.i3.212 Go to original source... Go to PubMed...
    7. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andrén-Sandberg A, Asbun HJ, Bockhorn M, Büchler MW, Conlon KC, Fernández-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM; International Study Group on Pancreatic Surgery. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156:591-600. Go to original source... Go to PubMed...
    8. Matsueda K, Kanzaki H, Matsueda K, Nasu J, Yoshioka M, Nakagawa M, Inoue M, Inaba T, Imagawa A, Takatani M, Takenaka R, Suzuki S, Tomoda J, Yagi T, Fujiwara T, Tanaka T, Okada H. The clinicopathological differences of sporadic non-ampullary duodenal epithelial neoplasm depending on tumor location. J Gastroenterol Hepatol 2019;34:1540-1544. doi: 10.1111/jgh.14640 Go to original source... Go to PubMed...
    9. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-96. doi: 10.1097/SLA.0b013e3181b13ca2 Go to original source... Go to PubMed...
    10. Xue Y, Vanoli A, Balci S, Reid MM, Saka B, Bagci P, Memis B, Choi H, Ohike N, Tajiri T, Muraki T, Quigley B, El-Rayes BF, Shaib W, Kooby D, Sarmiento J, Maithel SK, Knight JH, Goodman M, Krasinskas AM, Adsay V. Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. Mod Pathol 2017;30:255-266. doi: 10.1038/modpathol.2016.174 Go to original source... Go to PubMed...
    11. Tol JA, Brosens LA, van Dieren S, van Gulik TM, Busch OR, Besselink MG, Gouma DJ. Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer. Br J Surg 2015;102:237-45. doi: 10.1002/bjs.9709 Go to original source... Go to PubMed...
    12. Reid MD, Balci S, Ohike N, Xue Y, Kim GE, Tajiri T, Memis B, Coban I, Dolgun A, Krasinskas AM, Basturk O, Kooby DA, Sarmiento JM, Maithel SK, El-Rayes BF, Adsay V. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod Pathol 2016;29:1575-1585. doi: 10.1038/modpathol.2016.124 Go to original source... Go to PubMed...
    13. Ushiku T, Arnason T, Fukayama M, Lauwers GY. Extra-ampullary duodenal adenocarcinoma. Am J Surg Pathol 2014;38:1484-93. doi: 10.1097/PAS.0000000000000278 Go to original source... Go to PubMed...
    14. Liu N, Liang H, Zhang RP, Pan Y, Liu Y, Deng JY, Wang XN, Ding XW, Hao XS. Number of lymph node metastases: a significant prognostic factor for patients with radical resection of carcinoma of the ampulla of Vater. Zhonghua Wei Chang Wai Ke Za Zhi 2007;10:350-2. Go to PubMed...
    15. Ryska M, Hrabal P. Malignang tumors of duodenum. Rozhl Chir 2015;94:497-503. Go to PubMed...
    16. Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M; Japan Duodenal Cancer Guideline Committee. The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry. J Gastroenterol Hepatol 2020. doi: 10.1111/jgh.15285 Epub ahead of print Go to original source... Go to PubMed...
    17. Buchbjerg T, Fristrup C, Mortensen MB. The incidence and prognosis of true duodenal carcinomas. Surg Oncol 2015;24:110-6. doi: 10.1016/j.suronc.2015.04.004 Go to original source... Go to PubMed...
    18. Jiang QL, Huang XH, Chen YT, Zhang JW, Wang CF. Prognostic Factors and Clinical Characteristics of Patients with Primary Duodenal Adenocarcinoma: A Single-Center Experience from China. Biomed Res Int 2016;2016:6491049. doi: 10.1155/2016/6491049 Go to original source... Go to PubMed...
    19. Nitta N, Ohgi K, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Sasaki K, Uesaka K. Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience. Ann Surg Oncol 2020;27:4553-560. doi: 10.1245/s10434-020-08512-8 Go to original source... Go to PubMed...
    20. Solaini L, Jamieson NB, Metcalfe M, Abu Hilal M, Soonawalla Z, Davidson BR, McKay C, Kocher HM; UK Duodenal Cancer Study Group. Outcome after surgical resection for duodenal adenocarcinoma in the UK. Br J Surg 2015;102:676-81. doi: 10.1002/bjs.9791 Go to original source... Go to PubMed...
    21. Malleo G, Tonsi A, Marchegiani G, Casarotto A, Paiella S, Butturini G, Salvia R, Bassi C. Postoperative morbidity is an additional prognostic factor after potentially curative pancreaticoduodenectomy for primary duodenal adenocarcinoma. Langenbecks Arch Surg 2013;398:287-94. doi: 10.1007/s00423-012-0978-9 Go to original source... Go to PubMed...
    22. Kulu Y, Schmied BM, Werner J, Muselli P, Büchler MW, Schmidt J. Total pancreatectomy for pancreatic cancer: indications and operative technique. HPB (Oxford) 2009;11:469-75. doi: 10.1111/j.1477-2574.2009.00085.x Go to original source... Go to PubMed...
    23. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008;113:2038-45. doi: 10.1002/cncr.23822 Go to original source... Go to PubMed...
    24. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009;27:2598-603. doi: 10.1200/JCO.2008.19.7145 Go to original source... Go to PubMed...
    25. Lee HG, You DD, Paik KY, Heo JS, Choi SH, Choi DW. Prognostic factors for primary duodenal adenocarcinoma. World J Surg 2008;32:2246-52. Go to original source... Go to PubMed...
    26. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005;10:132-37. Go to original source... Go to PubMed...
    27. Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Kaufman HS, Hruban RH, Yeo CJ. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg 1998;2:79-87. doi: 10.1016/s1091-255x(98)80107-8 Go to original source... Go to PubMed...
    28. Poultsides GA, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, Pawlik TM, Herman JM, Edil BH, Ahuja N, Choti MA, Wolfgang CL, Schulick RD. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol 2012;19:1928-35. doi: 10.1245/s10434-011-2168-3 Go to original source... Go to PubMed...
    29. Mann K, Gilbert T, Cicconi S, Jackson R, Whelan P, Campbell F, Halloran C, Neoptolemos J, Ghaneh P. Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma. Langenbecks Arch Surg 2019;404:439-49. doi: 10.1007/s00423-019-01779-w Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content